Vaginal drug distribution modeling

Advanced Drug Delivery Reviews

Volumn 92, Issue , 2015, Pages 2-13

  Katz, David F ^a,b   Yuan, Andrew ^a   Gao, Yajing ^a  

^a Duke University   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gel; HIV; Microbicides; Modeling; Mucosa; Ring; Vagina

Indexed keywords

DRUG PRODUCTS; FORECASTING; GELS; MODELS; PRODUCT DESIGN; RINGS (COMPONENTS); STATISTICAL MECHANICS;

CONCENTRATION DISTRIBUTIONS; DIFFUSION AND CONVECTION; HIV; MICROBICIDES; MUCOSA; MULTIPLE APPLICATIONS; SOURCES OF VARIABILITY; VAGINA;

DRUG DOSAGE;

MICROBICIDE; TENOFOVIR; AGENTS USED INTRAVAGINALLY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ALLOMETRY; BODY MASS; CONCENTRATION (PARAMETERS); DETERMINISTIC MODELING; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RELEASE; DRUG STORAGE; DRUG TRANSPORT; FEMALE GENITAL TRACT PARAMETERS; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICATION COMPLIANCE; MODEL; PARITY; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; SHELF LIFE; STATISTICAL ANALYSIS; STROMA; THERMODYNAMICS; UTERINE CERVIX MUCUS; VAGINA; VAGINA EPITHELIUM; VAGINA RING; VAGINA SIZE; VAGINAL STROMA; VISCOSITY; ANATOMY AND HISTOLOGY; BIOLOGICAL MODEL; DRUG ABSORPTION; DRUG STABILITY; FEMALE; HIV INFECTIONS; PHYSIOLOGY;

ANTI-HIV AGENTS; DRUG STABILITY; FEMALE; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; VAGINA; VAGINAL ABSORPTION; VAGINAL CREAMS, FOAMS, AND JELLIES; VISCOSITY;

EID: 84943453044     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.04.017     Document Type: Review

References (64)

1. Barnhart K.T., Izquierdo A., Pretorius E.S., Shera D.M., Shabbout M., Shaunik A. Baseline dimensions of the human vagina. Hum. Reprod. 2006, 21:1618-1622.
2. Masters W.H., Johnson V.E. Human Sexual Response 1966, Little, Brown, Boston.
3. Owen D.H., Katz D.F. A vaginal fluid simulant. Contraception 1999, 59:91-95.
4. Harrison P.F., Rosenberg Z., Bowcut J. Topical microbicides for disease prevention: status and challenges. Clin. Infect. Dis. 2003, 36:1290-1294.
5. Faundes A., Brache V., Alvarez F. Pros and cons of vaginal rings for contraceptive hormone delivery. Am. J. Drug Deliv. 2004, 2:241-250.
6. Alexander N.J., Baker E., Kaptein M., Karck U., Miller L., Zampaglione E. Why consider vaginal drug administration?. Fertil. Steril. 2004, 82:1-12.
7. Brannon-Peppas L. Novel vaginal drug release applications. Adv. Drug Deliv. Rev. 1993, 11:169-177.
8. das Neves J.J., Bahia M.M.F. Gels as vaginal drug delivery systems 2006, 318:14.
9. Dobaria N., Mashru R., Vadia N.H. Vaginal drug delivery systems: a review of current status. East Cent. Afr. J. Pharm. Sci. 2007, 10:3-13.
10. Hussain A., Ahsan F. The vagina as a route for systemic drug delivery. J. Control. Release 2005, 103:301-313.
11. Balzarini J., Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 2007, 369:787-797.
12. Hladik F., Hope T.J. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep. 2009, 6:20-28.
13. Stone A. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat. Rev. Drug Discov. 2002, 1:977-985.
14. Kuo P.Y., Sherwood J.K., Saltzman W.M. Topical antibody delivery systems produce sustained levels in mucosal tissue and blood. Nat. Biotechnol. 1998, 16:163-167.
15. Saltzman W.M., Sherwood J.K., Adams D.R., Haller P. Long-term vaginal antibody delivery: delivery systems and biodistribution. Biotechnol. Bioeng. 2000, 67:253-264.
16. Dosage forms and delivery systems for vaginal therapy (special issue). Pharmaceutics 2014, 6.
17. das Neves J., Sarmento B. Drug Delivery and Development of Anti-HIV Microbicides 2014, Pan Stanford, Singapore.
18. Katz D.F. Biophysics, drug transport modeling and microbicides. Drug Delivery and Development of Anit-HIV Microbicides 2014, Pan Stanford Publishing, Singapore. J. das Neves, B. Sarmento (Eds.).
19. Saltzman W.M. Drug Delivery: Engineering Principles for Drug Therapy 2001, Oxford University Press.
20. Truskey G.A., Yuan F., Katz D.F. Transport Phenomena in Biological Systems 2004, Pearson/Prentice Hall, Upper Saddle River NJ.
21. Hendrix C.W., Cao Y.J., Fuchs E.J. Topical microbicides to prevent HIV: clinical drug development challenges. Annu. Rev. Pharmacol. Toxicol. 2009, 49:349-375.
22. Van Niekerk N., Nuttall J., Zeiser S., Nel A. Population pharmacokinetic modelling of dapivirine. AIDS Res. Hum. Retroviruses 2014, 30:A38-A39.
23. Yang K.-H., Schwartz J.L., Sykes C., Doncel G.F., Kashuba A.D.M. Population pharmacokinetic model of vaginal tenofovir 1% gel in the cervicovaginal fluid. AIDS Res. Hum. Retroviruses 2014, 30:A38-A38.
24. Hendrix C.W., Chen B.A., Guddera V., Hoesley C., Justman J., Nakabiito C., Salata R., Soto-Torres L., Patterson K., Minnis A.M., Gandham S., Gomez K., Richardson B.A., Bumpus N.N. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 2013, 8:e55013.
25. Saltzman W. Drug Delivery: Engineering Principles for Drug Therapy 2001, Oxford University Press, New York. 1 ed.
26. Katz D.F., Gao Y., Kang M. Using modeling to help understand vaginal microbicide functionality and create better products. Drug Deliv. Transl. Res. 2011, 1:256-276.
27. Kieweg S.L., Katz D.F. Squeezing flows of vaginal gel formulations relevant to microbicide drug delivery. J. Biomech. Eng.-Trans. ASME 2006, 128:540-553.
28. Kieweg S.L., Katz D.F. Interpreting properties of microbicide drug delivery gels: analyzing deployment kinetics due to squeezing. J. Pharm. Sci. 2007, 96:835-850.
29. Szeri A.J., Park S.C., Verguet S., Weiss A., Katz D.F. A model of transluminal flow of an anti-HIV microbicide vehicle: combined elastic squeezing and gravitational sliding. Phys. Fluids 2008, 20.
30. Tasoglu S., Katz D.F., Szeri A.J. Transient spreading and swelling behavior of a gel deploying an anti-HIV topical microbicide. J. Non-Newtonian Fluid Mech. 2012, 187-188:36-42.
31. Tasoglu S., Park S.C., Peters J.J., Katz D.F., Szeri A.J. The consequences of yield stress on deployment of a non-Newtonian anti-HIV microbicide gel. J. Non-Newtonian Fluid Mech. 2011, 166:1116-1122.
32. Tasoglu S., Peters J.J., Park S.C., Verguet S., Katz D.F., Szeri A.J. The effects of inhomogeneous boundary dilution on the coating flow of an anti-HIV microbicide vehicle. Phys. Fluids 2011, 23:93101-931019.
33. Ham A.S., Ugaonkar S.R., Shi L., Buckheit K.W., Lakougna H., Nagaraja U., Gwozdz G., Goldman L., Kiser P.F., Buckheit R.W. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J. Pharm. Sci. 2012, 101:1423-1435.
34. Mahalingam A., Smith E., Fabian J., Damian F.R., Peters J.J., Clark M.R., Friend D.R., Katz D.F., Kiser P.F. Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm. Res. 2010, 27:2478-2491.
35. Kiser P.F., Mahalingam A., Fabian J., Smith E., Damian F.R., Peters J.J., Katz D.F., Elgendy H., Clark M.R., Friend D.R. Design of tenofovir-UC781 combination microbicide vaginal gels. J. Pharm. Sci. 2012, 101:1852-1864.
36. Geonnotti A.R., Katz D.F. Compartmental transport model of microbicide delivery by an intravaginal ring. J. Pharm. Sci. 2010, 99:3514-3521.
37. Gao Y., Katz D.F. Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel. PLoS One 2013, 8:e74404.
38. Schwartz J.L., Rountree W., Kashuba A.D.M., Brache V., Creinin M.D., Poindexter A., Kearney B.P. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 2011, 6:e25974.
39. Gao Y., Yuan A., Katz D.F. Mass transport theory improves compartmental PK modeling of microbicides and helps guide product science and development. AIDS Res. Hum. Retroviruses 2014, 30:A147-A147.
40. Gao Y., Yuan A., Katz D.F. Tenofovir diphosphate concentrations in human vaginal stroma after different dosage regimens with a vaginal gel: a modeling approach. AIDS Res. Hum. Retroviruses 2014, 30:A258-A259.
41. Gao Y., Yuan A., Chuchuen O., Ham A., Yang K.H., Katz D.F. Vaginal deployment and tenofovir delivery by microbicide gels. Drug Deliv. Transl. Res. 2015, 5:279-294.
42. Chuchuen O., Henderson M.H., Sandros M.G., Kashuba A.D.M., Katz D.F. Transport and transport properties of tenofovir from microbicide gels into vaginal tissue: analysis using Raman spectroscopy. AIDS Res. Hum. Retroviruses 2014, 30:A59-A60.
43. Pendergrass P.B., Belovicz M.W., Reeves C.A. Surface area of the human vagina as measured from vinyl polysiloxane casts. Gynecol. Obstet. Invest. 2003, 55:110-113.
44. Chuchuen O., Henderson M.H., Sykes C., Kim M.S., Kashuba A.D.M., Katz D.F. Quantitative analysis of microbicide concentrations in fluids, gels, and tissues using confocal Raman spectroscopy. PLoS One 2013, 8:e85124.
45. Truskey G., Yuan F., Katz D. Transport Phenomena in Biological Systems 2009, Prentice Hall, Upper Saddle River, NJ. 2 ed.
46. Patton D.L., Thwin S.S., Meier A., Hooton T.M., Stapleton A.E., Eschenbach D.A. Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. Am. J. Obstet. Gynecol. 2000, 183:967-973.
47. Dobard C., Sharma S., Martin A., Pau C.P., Holder A., Kuklenyik Z., Lipscomb J., Hanson D.L., Smith J., Novembre F.J., Garcia-Lerma J.G., Heneine W. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J. Virol. 2012, 86:718-725.
48. Nuttall J., Kashuba A., Wang R., White N., Allen P., Roberts J., Romano J. Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob. Agents Chemother. 2012, 56:103-109.
49. Gao Y., Yuan A., Katz D.F. Modeling of gel flow and drug transport in the vaginal mucosa for better microbicide gel design. Annual meeting of Biomedical Engineering Society, San Antonio, TX 2014.
50. Louissaint N.A., Cao Y.J., Skipper P.L., Liberman R.G., Tannenbaum S.R., Nimmagadda S., Anderson J.R., Everts S., Bakshi R., Fuchs E.J., Hendrix C.W. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res. Hum. Retroviruses 2013, 29:1443-1450.
51. Shen Z., Fahey J.V., Bodwell J.E., Rodriguez-Garcia M., Kashuba A.D., Wira C.R. Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture. PLoS One 2014, 9:e100863.
52. Morrow K.M., Fava J.L., Rosen R.K., Vargas S., Shaw J.G., Kojic E.M., Kiser P.F., Friend D.R., Katz D.F., Team P.L.S. Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties. Aids Res. Hum. Retroviruses 2014, 30:78-91.
53. van den Berg J.J., Rosen R.K., Bregman D.E., Thompson L.A., Jensen K.M., Kiser P.F., Katz D.F., Buckheit K., Buckheit R.W., Morrow K.M. "Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav. 2014, 18:862-870.
54. Karim Q.A., Karim S.S.A., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., Kharsany A.B.M., Sibeko S., Mlisana K.P., Omar Z., Gengiah T.N., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D., Grp C.T. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
55. Rees H., Delany-Moretlwe S., Baron D., Lombard C., Gray G., Myer L., Panchia R., Schwartz J., Doncel G. FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women 2015, 26LB. CROI, Seattle, Washington.
56. Jeanne Marrazzo G.R., Nair G., Palanee T., Mkhize B., Nakabiito C., Taljaard M., Piper J., Gomez Feliciano K., Chirenje M., VOICE Study Team Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia 2013.
57. Katz D.F., Gao Y., Chang S. Multi-compartmental transport of anti-HIV molecules into and through mucosa. Biophys. J. 2012, 102:594a.
58. Dedrick R.L. Interspecies scaling of regional drug delivery. J. Pharm. Sci. 1986, 75:1047-1052.
59. Hunter R.P. Interspecies allometric scaling. Handb. Exp. Pharmacol. 2010, 139-157.
60. West G.B., Brown J.H. The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J. Exp. Biol. 2005, 208:1575-1592.
61. Leckie P.A., Watson J.G., Chaykin S. An improved method for the artificial insemination of the mouse (Mus musculus). Biol. Reprod. 1973, 9:420-425.
62. Chuchuen O., Henderson M.H., Sykes C., Kim M.S., Kashuba A.D., Katz D.F. Quantitative analysis of microbicide concentrations in fluids, gels and tissues using confocal Raman spectroscopy. PLoS One 2013, 8:e85124.
63. Chuchuen O., Henderson M.H., Sandros M.G., Kashuba A.D.M., Katz D.F. Transport and transport properties of tenofovir from microbicide gels into vaginal tissue: analysis using Raman spectroscopy. Aids Res. Hum. Retroviruses 2014, 30:A59-A60.
64. Tasoglu S., Rohan L.C., Katz D.F., Szeri A.J. Transient swelling, spreading, and drug delivery by a dissolved anti-HIV microbicide-bearing film. Phys Fluids 2013, 25:31901.